Aileron Stock Today

ALRN
 Stock
  

USD 2.81  0.06  2.18%   

Market Performance
0 of 100
Odds Of Distress
Less than 36
Aileron Therapeutics is selling for 2.81 as of the 4th of December 2022. This is a 2.18 percent increase since the beginning of the trading day. The stock's open price was 2.75. Aileron Therapeutics has about a 36 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. Equity ratings for Aileron Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 9th of December 2021 and ending today, the 4th of December 2022. Click here to learn more.
CUSIP
00887A105
Fiscal Year End
December
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
29th of June 2017
Category
Healthcare
Classification
Health Care
Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts. Aileron Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 4.54 M outstanding shares of which 12.29 K shares are presently shorted by private and institutional investors with about 0.46 trading days to cover. More on Aileron Therapeutics

Moving against Aileron Therapeutics

-0.72MRNAModerna Potential GrowthPairCorr
-0.68JNJJohnson Johnson TrendingPairCorr
-0.67CATCaterpillar TrendingPairCorr
-0.66JPMJPMorgan Chase Fiscal Year End 13th of January 2023 PairCorr

Aileron Therapeutics Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Aileron Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Aileron Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Aileron Therapeutics generated a negative expected return over the last 90 days
Aileron Therapeutics has high historical volatility and very poor performance
Net Loss for the year was (26.16 M) with loss before overhead, payroll, taxes, and interest of (17.01 M).
Aileron Therapeutics currently holds about 32.38 M in cash with (23.75 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.36.
Aileron Therapeutics has a frail financial position based on the latest SEC disclosures
Latest headline from news.google.com: Aileron Therapeutics Regains Compliance with Nasdaq Listing Requirements - Marketscreener.com
President CEO, DirectorJoseph Yanchik
Fama & French Classification
Average Analyst Recommendation
Analysts covering Aileron Therapeutics report their recommendations after researching Aileron Therapeutics' financial statements, talking to executives and customers, or listening in on Aileron Therapeutics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Aileron Therapeutics. The Aileron consensus assessment is calculated by taking the average forecast from all of the analysts covering Aileron Therapeutics.
Strong Buy2 Opinions
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Aileron Therapeutics based on its profitability, leverage, liquidity, source of funds, and operating efficiency. It is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Aileron Therapeutics financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares Diluted14.3 M13.3 M
Significantly Up
Increasing
Slightly volatile
Weighted Average Shares14.3 M13.3 M
Significantly Up
Increasing
Slightly volatile
Current Liabilities4.3 M4.8 M
Moderately Down
Increasing
Slightly volatile
Total Liabilities10.4 M9.6 M
Significantly Up
Increasing
Slightly volatile
Total Debt166.3 K162 K
Fairly Up
Decreasing
Slightly volatile
Current Assets20.7 M19.6 M
Notably Up
Increasing
Slightly volatile
Total Assets26 M27.3 M
Sufficiently Down
Increasing
Slightly volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Aileron Therapeutics' available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Strong BuyOvervalued
Financial Strength
Aileron Therapeutics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Aileron Therapeutics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Aileron Therapeutics' financial leverage. It provides some insight into what part of Aileron Therapeutics' total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Aileron Therapeutics' books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Aileron Therapeutics deploys its capital and how much of that capital is borrowed.
Liquidity
Aileron Therapeutics cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 100 K in liabilities with Debt to Equity (D/E) ratio of 0.0, which may suggest the company is not taking enough advantage from borrowing. Aileron Therapeutics has a current ratio of 6.38, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Aileron Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Aileron Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Aileron Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Aileron to invest in growth at high rates of return. When we think about Aileron Therapeutics' use of debt, we should always consider it together with cash and equity.

Operating Cash Flow

(34.65 Million)
Aileron Therapeutics (ALRN) is traded on NASDAQ Exchange in USA and employs 9 people. Aileron Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with current market capitalization of 12.76 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Aileron Therapeutics's market, we take the total number of its shares issued and multiply it by Aileron Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Aileron Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 4.54 M outstanding shares of which 12.29 K shares are presently shorted by private and institutional investors with about 0.46 trading days to cover. Aileron Therapeutics currently holds about 32.38 M in cash with (23.75 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.36.
Check Aileron Therapeutics Probability Of Bankruptcy
Ownership
The market capitalization of Aileron Therapeutics is currently $12.76 Million. 30% of Aileron Therapeutics outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulation than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or about to change. Be advised that no matter how volatile the entity is, if the real value of the firm is more than the value suggested by the market, you should consider buying it.

Ownership Allocation (%)

Check Aileron Ownership Details

Aileron Stock Price Odds Analysis

Proceeding from a normal probability distribution, the odds of Aileron Therapeutics jumping above the current price in 90 days from now is under 95%. The Aileron Therapeutics probability density function shows the probability of Aileron Therapeutics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Aileron Therapeutics has a beta of 0.6038. This suggests as returns on the market go up, Aileron Therapeutics average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Aileron Therapeutics will be expected to be much smaller as well. Additionally, the company has a negative alpha, implying that the risk taken by holding this instrument is not justified. Aileron Therapeutics is significantly underperforming NYSE Composite.
  Odds Below 2.81HorizonTargetOdds Above 2.81
5.20%90 days
 2.81 
94.77%
Based on a normal probability distribution, the odds of Aileron Therapeutics to move above the current price in 90 days from now is under 95 (This Aileron Therapeutics probability density function shows the probability of Aileron Stock to fall within a particular range of prices over 90 days) .

Aileron Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Aileron Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Aileron Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Aileron Therapeutics' value.
InstituionSecurity TypeTotal SharesValue
Zimmer Partners LpCommon Shares10 K112 K
Worth Venture Partners LlcCall Options22.5 K257 K
Wells Fargo CompanyCommon Shares4400.0
View Aileron Therapeutics Diagnostics

Aileron Therapeutics Historical Income Statement

Aileron Therapeutics Income Statement is one of the three primary financial statements used for reporting Aileron's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Aileron Therapeutics revenue and expense. Aileron Therapeutics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Aileron Therapeutics Operating Expenses is quite stable at the moment as compared to the past year. The company's current value of Operating Expenses is estimated at 27.49 Million. Preferred Dividends Income Statement Impact is expected to rise to about 45.7 K this year, although the value of Consolidated Income will most likely fall to (28.2 M). View More Fundamentals

Aileron Stock Against Markets

Picking the right benchmark for Aileron Therapeutics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Aileron Therapeutics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Aileron Therapeutics is critical whether you are bullish or bearish towards Aileron Therapeutics at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Aileron Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Focused Opportunities Now

   

Focused Opportunities

Build portfolios using our predefined set of ideas and optimize them against your investing preferences
All  Next Launch Module

Aileron Therapeutics Corporate Directors

Aileron Therapeutics corporate directors refer to members of an Aileron Therapeutics board of directors. The board of directors generally takes responsibility for the Aileron Therapeutics' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Aileron Therapeutics' board members must vote for the resolution. The Aileron Therapeutics board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Jodie Morrison - Independent DirectorProfile
Armen Shanafelt - Independent DirectorProfile
Caleb Winder - Independent DirectorProfile
Josef Rickenbach - DirectorProfile

Invested in Aileron Therapeutics?

The danger of trading Aileron Therapeutics is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Aileron Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Aileron Therapeutics. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Aileron Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Please continue to Trending Equities. You can also try ETF Directory module to find actively traded Exchange Traded Funds (ETF) from around the world.

Complementary Tools for analysis

When running Aileron Therapeutics price analysis, check to measure Aileron Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aileron Therapeutics is operating at the current time. Most of Aileron Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aileron Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Aileron Therapeutics' price. Additionally, you may evaluate how the addition of Aileron Therapeutics to your portfolios can decrease your overall portfolio volatility.
Transaction History
View history of all your transactions and understand their impact on performance
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Is Aileron Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aileron Therapeutics. If investors know Aileron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aileron Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
12.8 M
Return On Assets
(0.45) 
Return On Equity
(0.81) 
The market value of Aileron Therapeutics is measured differently than its book value, which is the value of Aileron that is recorded on the company's balance sheet. Investors also form their own opinion of Aileron Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aileron Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aileron Therapeutics' market value can be influenced by many factors that don't directly affect Aileron Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aileron Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Aileron Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aileron Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.